1. Home
  2. SENEB vs MGTX Comparison

SENEB vs MGTX Comparison

Compare SENEB & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seneca Foods Corp. Class B

SENEB

Seneca Foods Corp. Class B

HOLD

Current Price

$142.49

Market Cap

880.5M

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$9.21

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SENEB
MGTX
Founded
1949
2015
Country
United States
United States
Employees
6895
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
880.5M
909.1M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SENEB
MGTX
Price
$142.49
$9.21
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$24.57
AVG Volume (30 Days)
496.0
646.7K
Earning Date
06-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.02
EPS
N/A
N/A
Revenue
N/A
$81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
N/A
N/A
P/E Ratio
$12.93
N/A
Revenue Growth
N/A
144.57
52 Week Low
$90.19
$5.02
52 Week High
$164.98
$11.85

Technical Indicators

Market Signals
Indicator
SENEB
MGTX
Relative Strength Index (RSI) 58.50 46.35
Support Level $131.45 $8.75
Resistance Level $164.98 $9.65
Average True Range (ATR) 0.86 0.43
MACD -1.00 -0.09
Stochastic Oscillator 32.93 21.87

Price Performance

Historical Comparison
SENEB
MGTX

About SENEB Seneca Foods Corp. Class B

Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: